

Performance Against Initiation Benchmark

REC Number	IRAS Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Reasons for delay correspond to:					
15/SC/0103	154496	SCALOP-2: Systemic therapy and Chemoradiation in Advanced Localised Pancreatic cancer - 2	22/03/2016	27/04/2016	Benchmark Met					
16/SW/0032	190476	My Health Tags - To Improve Taking Tablets For Heart Failure	23/03/2016	14/06/2016	Sponsor					
16/SC/0018	191267	Study of CTX 4430 in Cystic Fibrosis Patients	31/03/2016	22/09/2016	Neither					
15/LO/1464	174042	DARS	29/03/2016	23/09/2016	Neither					
15/NE/0274	181026	EORTC 1320	24/03/2016	05/07/2016	Neither					
14/EE/1293	164389	C-STICH	25/02/2016	16/06/2016	Both					
14/LO/1644	137028	WT1TCR -002 Phase I/II study of genemodified WT1 TCR therapy in MDS & AML patient	28/04/2016	27/07/2016	Sponsor					
15/LO/0141	169126	OPHT 3845	24/03/2016		Neither					
15/LO/0413	171579	Safety and Efficacy of Brimonidine-DDS in patients with GA-AMD	12/05/2016	01/07/2016	Benchmark Met					
15/LO/0710	177905	EMBARK:MDV3100-13 Phase3, Enzalutamide, nonmetastatic Prostate Cancer	17/05/2016		Neither					
15/YH/0478	186697	REGENERATE: A Phase 3, DoubleBlind, Randomized, LongTerm, PlaceboControlled, Multicenter Study	26/05/2016	30/10/2016	Neither					
15/ES/0001	193859	GED-0301-CD-002 PhIII study for subjects with Active Crohn's Disease (REVOLVE)	27/04/2016	09/09/2016	Sponsor					
14/LO/2061	162162	PIMS	07/06/2016	02/12/2016	Both					
15/EE/0464	183877	CRIT 4440	03/06/2016	14/09/2016	Sponsor					
14/ES/1064	143994	LOGS - A randomised phase II/II study to assess the efficacy of Trametinib (GSK 1120212) in patients with	15/06/2016		Neither					
15/WA/0316	182694	MyeChild 01	15/06/2016	19/10/2016	Neither					
14/NW/1110	149572	rEECur	29/03/2016		Neither					
14/SC/1416	156215	Immunoglobulin in the Treatment of Encephalitis (The IgNiTE study)	23/03/2016		Neither					
15/LO/0769	155035	Left Atrial Appendage Occlusion Study III (LAAOS III)	27/07/2016	27/11/2016	Sponsor					
16/SW/0069	181429	Dynamic hormone diagnostics (ULTRADIAN)	29/02/2016	03/10/2016	Sponsor					
16/EE/0105	191013	Zoledronic acid in Malignant pleural mesothelioma undergoing palliative chemotherapy:	26/09/2016	14/03/2017	Neither					
15/EM/0103	130101	SIOP Ependymoma II	04/11/2016		Neither					
REC Number	IRAS Number	Name of Trial	HRA Approval Date	Date Site Invited	Date Site Selected	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
16/LO/0814	199311	CHIL4593 - Sarilumab, administered with subcutaneous (SC) injection, in patients aged 2 to 17, with polyarticular-course juvenile idiopathic arthritis (pcJIA) followed by an extension phase	06/07/2016	07/04/2016	05/05/2016	16/08/2016	17/08/2016	05/09/2016		Neither
16/WM/0276	207822	Safety of Nasal Influenza Immunisation in Children with Asthma: The SNIFFLE 4 study	22/08/2016	08/07/2016	05/10/2016	05/10/2016	11/10/2016	13/10/2016	20/10/2016	Benchmark Met
16/WM/0359	211812	Blinatumomab in Aggressive B-Cell Non Hodgkin Lymphoma	12/10/2016	24/08/2016	27/10/2016	03/11/2016	03/11/2016	23/11/2016	10/04/2017	Neither
16/LO/0581	194313	C31004	11/08/2016	01/08/2016	14/09/2016	25/10/2016	16/11/2016	16/02/2017		Neither
16/EE/0243	207331	EARN 30709	01/08/2016	22/08/2016	10/10/2016	16/11/2016	17/11/2016	24/01/2017	26/01/2017	Neither
16/SC/0161	186322	GO29438 PhaseIII Study-Atezolizumab with chemotherapy in Stage IV Non-Squamous	12/05/2016	23/09/2016	16/11/2016	01/12/2016	01/12/2016	05/12/2016	22/12/2016	Benchmark Met

Performance Against Initiation Benchmark

16/SC/0542	208245	OMASPECT	09/11/2016	04/11/2016	25/11/2016	29/11/2016	19/12/2016	19/12/2016	13/01/2017	Benchmark Met
16/EM/0408	211983	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	02/12/2016	18/10/2016	05/12/2016	22/12/2016	23/12/2016	29/12/2016	08/02/2017	Benchmark Met
16/NW/0750	209722	A study to evaluate the acceptability of ZestiVits;	09/11/2016	06/09/2016	01/11/2016	02/11/2016	17/11/2016	17/02/2017		Sponsor
16/WA/0159	162019	EMPHIS	05/12/2016		05/12/2016	05/12/2016	06/12/2016			Sponsor
16/SW/0098	184167	BIG ROMIO (RCT of minimally invasive or open oesophagectomy)	09/08/2016	28/09/2016	28/09/2016	04/10/2016	03/10/2016	05/10/2016	20/10/2016	Benchmark Met
16/SC/0416	210405	Safety & Efficacy of MEDI8897	30/09/2016	26/08/2016	13/10/2016	24/10/2016	28/10/2016	17/11/2016	14/12/2016	Benchmark Met
16/SW/0201	205118	OPHT 5713	19/10/2016	01/07/2016	06/12/2016	25/11/2016	05/01/2017	27/01/2017	28/03/2017	Neither
16/SC/0530	213306	Ketocal 2.5:1 LQ tolerance trial	05/12/2016	17/10/2016	15/12/2016	03/01/2017	09/01/2017	11/01/2017		Neither
16/LO/1612	201997	Follow-up Study for Patients who Completed Study ALX0681-C301	16/11/2016	10/08/2016	14/10/2016	09/01/2017	11/01/2017	19/01/2017	24/01/2017	Both
16/SC/0277	202191	Point Of Care Testing For Sepsis: A Diagnostic Accuracy Study	18/10/2016	04/10/2016	12/01/2017	04/10/2016	13/01/2017	03/02/2017	16/03/2017	Benchmark Met
16/LO/0831	196728	CAP-IT	11/11/2016	09/09/2016	22/09/2016	18/01/2017	20/01/2017	08/02/2017	23/03/2017	Sponsor
16/LO/1069	200813	PALLAS: PALbociclib CoLLaborative Adjuvant Study	06/09/2016	08/08/2016	08/08/2016	26/01/2017	01/02/2017	01/02/2017		Sponsor
16/SW/0332	150874	DIAPASS- Ayendi Observational Study	05/12/2016	16/12/2016	06/02/2017	17/02/2017	20/02/2017	20/02/2017	24/02/2017	Benchmark Met
16/SC/0350	199995	Does a ketogenic diet reduce delirium in Intensive Care. Part I - A feasibility study to test if a ketogenic diet causes ketosis in patients on Intensive Care.	20/02/2017		20/02/2017	20/02/2017	21/02/2017	21/02/2017		Not Yet 70 days
16/EE/0463	214371	CompLEEment-1	30/01/2017	08/08/2016	20/02/2017	30/01/2017	21/02/2017	15/03/2017	30/03/2017	Benchmark Met
16/LO/1960	199019	Dose finding study of Sarilumab in children with sJIA	28/02/2017	08/11/2016	19/12/2016	24/01/2017	01/03/2017			Sponsor
16/WA/0069	198007	Clinical efficacy and mechanistic evaluation of Eplerenone for central serous chorio-retinopathy - the VICI study	21/07/2016	19/07/2016	08/02/2017	02/03/2017	09/03/2017	17/03/2017	31/03/2017	Benchmark Met
17/LO/0017	213632	Open-label Extension Study for Participants with Prostate Cancer	08/03/2017	05/08/2016	09/03/2017	15/02/2017	13/03/2017			Not Yet 70 days